Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bms 742413
2. Bms-742413
3. N-(3-(7-methyl-1h-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl))-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
1. Vazegepant
2. Bms-742413
3. Bhv-3500
4. Zavegepant [usan]
5. Odu3zaz94j
6. Bms-742413-01
7. 1337918-83-8
8. Chembl2397415
9. N-[(2r)-3-(7-methyl-1h-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1h-quinolin-3-yl)piperidine-1-carboxamide
10. 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-
11. 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-1-piperidinecarboxamide
12. Zavegepant [inn]
13. Unii-odu3zaz94j
14. Vazegepant [who-dd]
15. Schembl107428
16. Gtpl11513
17. Ex-a6698
18. Bdbm50436107
19. Bms742413
20. Who 11512
21. Hy-134992
22. Cs-0168642
Molecular Weight | 638.8 g/mol |
---|---|
Molecular Formula | C36H46N8O3 |
XLogP3 | 3.1 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 6 |
Exact Mass | 638.36928736 g/mol |
Monoisotopic Mass | 638.36928736 g/mol |
Topological Polar Surface Area | 117 Ų |
Heavy Atom Count | 47 |
Formal Charge | 0 |
Complexity | 1160 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
About the Company : Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...
About the Company : Farmhispania Group comprises two companies in Spain: Farmhispania in Barcelona and Rolabo in Zaragoza. Since its inception, the group has consistently invested in advanced equipmen...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Apicore LLC, a wholly owned subsidiary of RK Pharma Inc is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. We offer a wide p...
About the Company : Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharm...
About the Company : Saptagir Laboratories Private incorporated in 2016, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) and Intermediates for a wide range of therapeutic cat...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Zavzpret (zavegepant) is a calcitonin gene-related peptide receptor antagonist. CGRP antagonists have been shown pain relief during migraine induced headaches.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: Zavzpret
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2023
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Details : Zavzpret (zavegepant) is a calcitonin gene-related peptide receptor antagonist. CGRP antagonists have been shown pain relief during migraine induced headaches.
Product Name : Zavzpret
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2023
Details:
Pfizer has given Royalty Pharma an accelerated milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant). Zavzpret was approved by the U.S. FDA, which provides another important new treatment option for migraine patients.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: Zavzpret
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Pfizer Inc
Deal Size: $475.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2023
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $475.0 million
Deal Type : Agreement
Royalty Pharma Nabs $475M Milestone from Pfizer upon Migraine Nasal Spray
Details : Pfizer has given Royalty Pharma an accelerated milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant). Zavzpret was approved by the U.S. FDA, which provides another important new treatment option for migraine patie...
Product Name : Zavzpret
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 15, 2023
Details:
Complete data from the Phase 3 BHV3500 (zavegepant) nasal spray study highlight its ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: BHV-3500
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 13, 2022
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Complete data from the Phase 3 BHV3500 (zavegepant) nasal spray study highlight its ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose.
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 13, 2022
Details:
In the pivotal studies, BHV3500 (zavegepant) was statistically superior to placebo on the coprimary regulatory endpoints of superiority to placebo at 2 hours for pain freedom and freedom from the migraine-associated most bothersome.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: BHV-3500
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2022
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the pivotal studies, BHV3500 (zavegepant) was statistically superior to placebo on the coprimary regulatory endpoints of superiority to placebo at 2 hours for pain freedom and freedom from the migraine-associated most bothersome.
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Details:
Biohaven plans to file a NDA for BHV-3500 (zavegepant) with the USFDA in 1Q2022,showed ultra-rapid pain relief at the earliest measured time point of 15 minutes and sustained efficacy through 48 hours after a single intranasal dose.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: BHV-3500
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2021
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Biohaven plans to file a NDA for BHV-3500 (zavegepant) with the USFDA in 1Q2022,showed ultra-rapid pain relief at the earliest measured time point of 15 minutes and sustained efficacy through 48 hours after a single intranasal dose.
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2021
Details:
Zavegepant is a high affinity, selective and structurally unique, third generation, CGRP receptor antagonist in development for both migraine and non-migraine CGRP-mediated diseases.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: BHV-3500
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 29, 2021
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zavegepant is a high affinity, selective and structurally unique, third generation, CGRP receptor antagonist in development for both migraine and non-migraine CGRP-mediated diseases.
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 29, 2021
Details:
Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: BHV-3500
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 09, 2020
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation.
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2020
Details:
Biohaven plans to study intranasal vazegepant, a high affinity, selective and structurally unique, small molecule CGRP receptor antagonist, in pulmonary complications of COVID-19 disease.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Infections and Infectious Diseases Brand Name: BHV-3500
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 04, 2020
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant
Details : Biohaven plans to study intranasal vazegepant, a high affinity, selective and structurally unique, small molecule CGRP receptor antagonist, in pulmonary complications of COVID-19 disease.
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2020
Details:
Funding will advance the Biohaven's CGRP receptor antagonist program through the development of zavegepant (vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indications.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: BHV-3500
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Royalty Pharma
Deal Size: $450.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 08, 2020
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $450.0 million
Deal Type : Funding
Biohaven and Royalty Pharma Announce Funding Agreement
Details : Funding will advance the Biohaven's CGRP receptor antagonist program through the development of zavegepant (vazegepant). The zavegepant program encompasses intranasal zavegepant as well as oral zavegepant for migraine prevention and non-migraine indicati...
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 08, 2020
Details:
The Company addressed all issues raised by the FDA and will advance the 10 mg dose of intranasal vazegepant into a double-blind, placebo-controlled Phase 3 clinical trial.
Lead Product(s): Zavegepant HCl
Therapeutic Area: Neurology Brand Name: BHV-3500
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 23, 2020
Lead Product(s) : Zavegepant HCl
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migrain
Details : The Company addressed all issues raised by the FDA and will advance the 10 mg dose of intranasal vazegepant into a double-blind, placebo-controlled Phase 3 clinical trial.
Product Name : BHV-3500
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 23, 2020
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
85
PharmaCompass offers a list of Vazegepant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vazegepant manufacturer or Vazegepant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vazegepant manufacturer or Vazegepant supplier.
PharmaCompass also assists you with knowing the Vazegepant API Price utilized in the formulation of products. Vazegepant API Price is not always fixed or binding as the Vazegepant Price is obtained through a variety of data sources. The Vazegepant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Zavegepant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Zavegepant, including repackagers and relabelers. The FDA regulates Zavegepant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Zavegepant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Zavegepant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Zavegepant supplier is an individual or a company that provides Zavegepant active pharmaceutical ingredient (API) or Zavegepant finished formulations upon request. The Zavegepant suppliers may include Zavegepant API manufacturers, exporters, distributors and traders.
click here to find a list of Zavegepant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Zavegepant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Zavegepant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Zavegepant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Zavegepant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Zavegepant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Zavegepant suppliers with NDC on PharmaCompass.
Zavegepant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Zavegepant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Zavegepant GMP manufacturer or Zavegepant GMP API supplier for your needs.
A Zavegepant CoA (Certificate of Analysis) is a formal document that attests to Zavegepant's compliance with Zavegepant specifications and serves as a tool for batch-level quality control.
Zavegepant CoA mostly includes findings from lab analyses of a specific batch. For each Zavegepant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Zavegepant may be tested according to a variety of international standards, such as European Pharmacopoeia (Zavegepant EP), Zavegepant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Zavegepant USP).